Continuing Medical Education Opportunities

• Annual Meeting Webcasts

SSO Continuing Medical Education Monographs

• Minimizing and Managing the Toxicity of Melanoma Therapy (1.5 MB PDF)
  CME CREDIT EXPIRED: Term of approval for this CME monograph is from June 1, 2009 to July 1, 2010.
  —Based on a session presented at the 2009 SSO Annual Cancer Symposium
  VK Sondak, AMM Eggermont, JF Thompson, JS Weber
  • Complications of inguinal and ilioinguinal node dissection and significance of early treatment of metastatic disease in the groin • Utilizing ultrasound evaluation of regional lymph nodes to minimize adverse effects of lymph node dissection • Evidence for adjuvant therapy of high-risk melanoma • Current investigational approaches to adjuvant treatment, particularly to decrease morbidity compared to standard high-dose interferon • Theoretical basis for the results of clinical trials with anti-CTLA4 antibodies in the management of stage III and IV melanoma • Minimizing complications and adverse effects of anti-CTLA4 antibodies, particularly adverse effects requiring surgical evaluation and/or intervention
  This educational activity and newsletter were supported by an educational grant from Schering-Plough. The SSO designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™.
  
• Current Management of Melanoma: From Ambiguous Lesions to Metastatic Disease (3.14 MB PDF)
  CME CREDIT EXPIRED: Term of approval for this CME monograph is from June 1, 2008 to June 1, 2009
  —Based on a session presented at the 2008 SSO Annual Cancer Symposium
  MC Mihm, MI Ross, VK Sondak, CM Balch
  • Role of adjuvant radiation and other treatments with surgery in management of regional nodal disease • Selection criteria and results of surgery in the multi-modality approach to management of stage IV melanoma • Characteristics of primary and metastatic melanoma to predict metastatic risk and survival outcomes • TNM criteria and stage grouping for melanoma staging system.
  This educational activity and newsletter were supported by an educational grant from Schering-Plough Corporation. SSO designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™.
  
• Multidisciplinary Management of Primary and Metastatic GIST (2.42 MB PDF)
  CME CREDIT EXPIRED: Term of approval for this CME monograph is from June 1, 2008 to June 1, 2009
  —Based on a session presented at the 2008 SSO Annual Cancer Symposium
  RP DeMatteo, CP Raut, CD Blanke, CL Corless
  • Complexity of managing primary and metastatic GIST in providing the best in GIST care • Importance of the EORTC Phase I/II and CSTI571 B2222
  Phase II trials in regards to GIST management • Impact of KIT and PDGFRA mutations on outcome and response to TKI therapy
  This educational activity is supported by educational grants from Pfizer Inc. and Novartis Pharmaceuticals Corporation. The Peer•Point Medical Education Institute, LLC, has collaborated with the Society of Surgical Oncology to develop this enduring educational program. SSO designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit ™.
  
• Targeted Therapy in the Surgical Patient with Breast Cancer (3.14 MB PDF)
  CME CREDIT EXPIRED: Term of approval for this CME monograph is from June 1, 2008 to June 1, 2009
  —Based on a session presented at the 2008 SSO Annual Cancer Symposium
  CM Balch, FJ Esteva, WJ Gradishar, F  Meric-Bernstam
  • Indications for ordering HER2 receptor assay and differences in interpreting FISH and RT-PCR results • Indications for using trastuzumab and other novel targeted agents based upon evidence from prospective clinical trials, including risks and side effects • Rationale for current clinical trials and background evidence that led to current trials for neoadjuvant targeted therapies • How to participate in current clinical trials involving neoadjuvant and adjuvant targeted therapies • Types of emerging predictive markers of response and pharmacodynamic marker of response • New targeted agents representing next generation of targeted therapy in breast cancer.
  This educational activity and newsletter were supported by an educational grant from Genentech. The SSO designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™.